Concurrent inhibition of the “Tumor Microenvironment”, “Wound Healing”, and “Estrogen Receptor” pathways suggests selective hematopoietic engagement while minimizing proinflammatory or proliferative responses. Here, ESR1 is linked to neoplasm.